You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. N/A

    SBC: Generx+, Inc.            Topic: N/A

    N/A

    STTR Phase II 2000 Department of Health and Human ServicesNational Institutes of Health
  2. N/A

    SBC: SPECTRUMEDIX CORPORATION            Topic: N/A

    N/A

    STTR Phase II 2000 Department of Health and Human ServicesNational Institutes of Health
  3. TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION

    SBC: Azevan Pharmaceuticals Inc            Topic: N/A

    Serenix Pharmaceuticals LLC (SPL) will develop drugs to treat impulsivity, violence and self-injurious behavior in patients with autism, Tourette's syndrome, and mental retardation. These drugs, termed serenics, stop violent behavior without disrupting normal behaviors. No other products are available for these indications. SPL required a series of vasopressin receptor antagonists from Eli Lilly C ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  4. P20, MOLECULAR SHORTSTOP FOR INFLAMMATORY LUNG DISEASES

    SBC: Generx+, Inc.            Topic: N/A

    The transcription factor CAAT enhancer binding protein beta (C/EBPbeta) is a key factor orchestrating the inflammatory response. Specifically, expression of the genes encoding the pro-inflammatory cytokines IL-6 and on IL-8 are regulated by C/EBPbeta. C/EBPbeta can be either an activator or an inhibitor of inflammation depending on the dominant isoforms produced. Our data indicate that airway epit ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  5. FREQUENCY DOMAIN CEREBRAL OXIMETER FOR PEDIATRICS

    SBC: INFRASCAN INC            Topic: N/A

    Brain damage from hypoxia-ischemia represents a major health problem in pediatrics. At present, no method exists in clinical care to diagnose cerebral hypoxia-ischemia in real-time at the bedside, thereby limiting prevention and treatment of the brain damage. Near infrared spectroscopy (cerebral oximetry) is an emerging optical technology with the potential to fulfill this role. In previous work, ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  6. Ultrasonic Registration of Knee Anatomy to MRI Images

    SBC: BLUE BELT TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The proposed research will investigate the feasibility of using intra-operative ultrasound (US) images to non-invasively register the bone surfaces of the knee to preoperative magnetic resonance (MR) images. A surgical navigation system, KneeNav, is being developed by CASurgica for intraoperatively planning the proper location of ligament attachment sites and d ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  7. TGF-beta for Pleurodesis

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 50,000 cancer patients a year have recurrent fluid accumulation in the space between their chest wall and lung. This condition is called malignant pleural effusion (MPE). This fluid impairs breathing and worsens the quality of life in these patients. The current treatments are not ideal and include removing the fluid by repetitive needle aspiratio ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  8. A web-based IT Solution for Outcome Based Prevention

    SBC: Kit Solutions, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The major objective of Phase II is to fully develop iGTO into a product that is ready for large-scale commercial distribution and deployment. iGTO is a capacity-building system designed to help practitioners demonstrate results. Utilizing an innovative interactive web-based technology, the iGTO system uses science and "best practices" to help practitioners and ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  9. Gene Expression and Diagnosis of Diabetes

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be nonspecific. A single test that could readily distinguish between an autoimmune and non-autoimmune disorder would allow physicians to focus efforts on the specific disease that affects the patient. This is critical for diabetes mellitus (DM), which has two subsets, Type I and Type II. The sub ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Modified Tetracycline Effect on Sepsis-Induced Mortality

    SBC: Collagenex Pharmaceuticals, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): It was our Specific Aim in Phase I to: 1) develop a clinically relevant indirect sepsis-induced acute respiratory distress syndrome (ARDS) model and 2) utilize this model to determine the efficacy of prophylactic COL-3 in preventing the onset of ARDS. Both goals of our Phase I study were achieved and the results are as follows: 1) we successfully developed an ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government